Journal publications in English

  1. Blahoš J., Svoboda Z., Höschl C.: The effect of calcitonine on glucose metabolism. Endokrinologie 68, 1976 ,s.226-230.
  2. Höschl C.: Lithium influence on TSH response to TRH in depressed patients. Physiologia Bohemoslovaca, 30, 1981, 1: 89-90.
  3. Höschl C.: Effect of lithium on the TRH-test. Activ. nerv. sup., 23, 1981, 4: 276-278.
  4. Höschl C, Stárka L, Roth Z, Vokálková J, Jaššová J. A specific laboratory test for primary depression. Acta Univ. Carolinae Medica, 31, 1985, No. 5-6, pp: 347-364.
  5. Höschl C., Kožený J.: DST in Czechoslovakia. Biol. Psych., 21, 1986, 11: 1103-1104.
  6. Höschl C., Kožený J.: Verapamil in affective disorders: a double-blind, controlled study. Biol. Psychiat., 25, 1989, 2: 128-140.
  7. Höschl C.: Do Calcium Antagonists Have a Place in the Treatment of Mood Disorders? Drugs, 42,1991,5: 721-729. Reprinted in: New Ethicals, May 1992: 139-149.
  8. Höschl C., Vacková J., Janda B.: Mood stabilizing effect of verapamil. Bratisl. Lek. Listy, 93,1992,4:208-209
  9. Höschl C.: Prediction: Nonsense or Hope? Br.J.Psychiat., 163 (suppl.21), 1993: 46-54.
  10. Filip V., Höschl C., Karen P., Seifertová D., Bornová L., Prašková H., Praško J.: Predicting Therapeutic Results with Levoprotiline and Maprotiline in Major Depression: The Role of the Outcome Criteria. Br.J.Psychiat., 163 (suppl.21), 1993: 35-38
  11. Řípová D, Němcová V, Farská I, Papežová H, Höschl C: Changes in platelet phospholipid content in treated and untreated schizophrenics. Eur.Neuropsychopharmacol. 3 (3), 1993: 395.
  12. Řípová D., Němcová V., Höschl C., Strunecká A.: Effect of chlorpromazine (CPZ) on phosphoinositide-signalling system in human platelets. Cell Biology International 18,1994,5: 489
  13. Řípová D., Němcová V., Růžička P., Strunecká A., Höschl C.: Phosphoinositide-signalling system in resting platelets of schizophrenics. European Neuropsychopharmacology 4, 1994, 3: 372.
  14. Řípová D., Němcová V., Strunecká A., Höschl C.: Inositol triphosphate and cytosolic calcium level in activated plate lets of schizophrenics. European Neuropsychopharmacology 4, 1994, 3: 371.
  15. David I., Filip V., Höschl C., Libiger J. Karen P.: Possible prediction of therapeutic outcome based on single dose effect of levoprotiline and maprotiline on C-EEG. Homeostasis, 35, 1994, 6: 292-293.
  16. Goodwin GM, Nolen WA: Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy. (Group: Bourgeois ML, Conti L, Fischer P, Gastpar M, Griffiths JM, Höschl C, Kapitany T, Malt UF, Muscettola G, Papadimitriou GN, Potter WZ, Puzynski S, Swinkels JA, Zarate CA jr.). International journal of Psychiatry in Clinical Practice 1, 1997: S9-S12.
  17. Höschl C., Kožený J.: Predicting academic performance of medical students: The first three years. Am. J. Psychiatry, 154, 1997, 6: 87-92.
  18. Kožený J., Höschl C.: The temperament and character inventory: psychometric integrity of the Czech version. Studia psychologica 41, 1999, 2:123-132.
  19. Řípová D., Strunecká A., Platilová V., Höschl C.: Phosphoinositide signalling system in platelets of schizophrenic patients and the effect of neuroleptic therapy. Prostaglandins, Leukotrienes and Essential Fatty Acids, 61, 1999, 2:125-129.
  20. Horáček J., Kuzmiaková M., Höschl C., Anděl M., Bahbouh R.: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 24/1999:785-797.
  21. Höschl C., Libiger J.: Rights and responsibilities of the psychiatric profession: Limits of Psychiatry. Psychiatrie 3, 1999, 4:288-289.
  22. Höschl C., Libiger J. Rights and responsibilities of the psychiatric profession. Acta Psychiatrica Scandinavica 101, 2000, Suppl. 3999:40-41.
  23. Höschl C.: Introduction (Editorial). In: Dose M., Höschl C. (eds): Movement disorders in psychiatry, specifically to drug-induced dyskynesias. Pharmacopsychiatry 33, 2000, S1, pp. 1 – 48. Thieme, Stuttgart – New York 2000. ISSN 0936-9589.
  24. Řípová D., Platilová V., Strunecká D., Jirák R., Höschl C.: Cytosolic calcium alterations in platelets of patients with early stages of Alzheimer´s disease. Neurobiology of Aging 21, 2000:729-734. IF = 3,517. ISSN:
  25. Horáček J., Libiger J., Höschl C., Borzová K., Hendrychová, I. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int. J. Psychiatry in Clin. Pract., 5, 2001:71-73.
  26. Höschl C., Hájek T.: Hippocampal damage mediated by corticosteroids – a neuropsychiatric research challenge. Eur. Arch. Psychiatry Clin Neurosci 2001, 251:Supp.2,II/81-II/88.
  27. Hájek T., Pašková B., Janovská D., Bahbouh R., Hájek P., Libiger J., Höschl C.: Higher prevalence of antibodies to borrelia burgdorferi in psychiatric patients than in healthy subjects. Am J Psychiatry 2002 Feb.; 159(2):297-301.
  28. Balon R., Höschl C.: Research training in the Czech Republic. Academic Psychiatry 26; 2002, 2:125-127.
  29. Kopeček M., Höschl C., Hájek T. Regional selectivity of novel antipsychotics. Br. J. Psychiat. 181,2002, 9:254-255.
  30. Bauer M, Whybrow PC, Angst J, et al.,WFSBP Task Force (...Höschl C...): (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorder and subtreshold depressions.The World Journal of Biological Psychiatry 2002,3: 69-86
  31. Bauer M, Whybrow PC, Angst J, et al.,WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (...Höschl C...): (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. The World Journal of Biological Psychiatry 2002, 3: 5-43
  32. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (.... Höschl C...):WFSBP Treatment Guidelines on Bipolar Disorders.The World Journal of Biological Psychiatry 3,2002:115-124
  33. Höschl C.: Commercial-academic interface: The need for ethical standards. Mental Health Reforms, 8, 2003; 1:6-7.
  34. Grunze H., Kasper S., Goodwin G., Bowden Ch., Baldwin D., Licht R.W., Vieta E., Möller H.J., WFSBP Task force on Treatment Guidelines for Bipolar Disorders (C. Höschl, member of task force): The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry, 4;2003, 5:5-13.
  35. Horáček J., Bubeníková V., Kopeček M., Brunovský M., Páleníček T., Höschl C.: From animal models to clinical treatment modalities in schizophrenia. Eur. Neuropsychopharmacology, 13, 2003, Suppl. 4:S158.
  36. Řípová D., Platilová V., Strunecká A., Jirák R., Höschl C.: Alterations in Calcium Homeostasis as Biological Marker for Mild Alzheimer´s Disease? Physiol. Res. 2004, 53:449-452.
  37. Grunze H., Kasper S., Goodwin G., Bowden Ch., Möller HJ. WFSBP Task force on Treatment Guidelines for Bipolar Disorders (C. Höschl, member of task force): The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. reatment Guidelines for bipolar disorders). World J Biol. Psychiatry, 2004, 5, 120-135.
  38. Höschl C.: Atypical antipsychotics in the treatment of schizophrenia. Advanced approaches to atypical antipsychotic tratment. Fujisawa, Japonsko, 2004, str. 1-4.
  39. Horáček J., Kopeček M., Španiel F., Mohr P., Dockery C., Seifertová D., Bělohlávek O., Höschl C.: Resting regional brain metabolism in patients with schizophrenia. 18FDG PET study. (Klidový regionální metabolizmus mozku u pacientů se schizofrení. Studie 18FDG PET). Psychiatrie, 8, 2004, S3:43-50.
  40. Höschl C., Praško J.: Management of depressed patients with sexual dysfunction. WPA Bulletin on Depression, 2004; 9, 28:11-14.
  41. Bubeníková V., Horáček J., Kožený J., Platilová V., Závěšická V., Höschl C.: The effect of tryptophan depletion on the action of haloperidol in MK-801 trated rats. European Journal of Pharmacology, 2004, Vol. 502; 1-2:109-116.
  42. Praško J., Horáček J., Záleský R., Kopeček M., Novák T., Pašková B., Škrdlantová L., Bělohlávek O., Höschl C.: The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuroendocrinology Letters 2004; 25(5):340-348.
  43. Horáček J., Závěšická L., Tintěra J., Dockery C., Platilová V., Kopeček M., Španiel F., Bubeníková V., Höschl C.: The effect of tryptophan depletion on brain activation measured by fMRI during the Stroop test in healthy subjects. Physiological Research, 2005, 54:235-244.
  44. Höschl C.: Helsinki Ministerial Conference – National Perspectives. Die Psychiatrie, 2005, 2:111-113. ISSN 1614-4864.
  45. Škrdlantová L., Horáček J., Dockery C., Lukavský J., Kopeček M., Preiss M., Novák T., Höschl C. The influence of low-frequency prefrontal rTMS on memory for words but not faces. Physiological Research 2005; 54,1: 123-128
  46. Španiel F., Herynek V., Hájek T., Dezortová M., Horáček J., Hájek M., Kožený J., Dockery C., Höschl C.: Magnetic resonance relaxometry in monozygotic twins discordant and concordant for schizophrenia. European Psychiatry, 20, 2005, 1:41-44.
  47. Hájek T., Libiger J., Janovská D., Hájek P., Alda M., Höschl C.: Clinical and demographic characteristics of psychiatric patients seropositive for Borrelia burgdorferi. European Psychiatry, 21, 2006, 2:118-122.
  48. Hájek T., Kopeček M., Preiss M., Alda M., Höschl C.: Prospective study of hippocampal volume and function in human subjects treated with corticosteroids. European psychiatry, 21, 2006, 2:123-128.
  49. Motlova L, Dragomirecka E, Spaniel F, Goppoldova E, Zalesky R, Selepova P, Figlova Z, Höschl C. Relapse prevention in schizophrenia: does group family psychoeducation matter? One-year prospective follow-up field study. Int J Psychiat Clin Pract, 2006; 10(1): 38-44
  50. Novák T, Horáček J, Mohr P, Kopeček M, Klírová M, Rodriguez M, Španiel F, Dockery C, Höschl C.The double-blind sham-controlled study of high-frequency rTMS (20Hz) for negative symptoms in schizophrenia: Negative results. Neuro Endocrinol Lett. 2006 Apr 25;27(1-2):209-213
  51. Horáček J., Bubeníková-Valešová V., Kopeček M., Páleníček T., Dockery C., Mohr P., Höschl C.: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. Drugs. 20, 2006; 5:389-409
  52. Bares M, Brunovsky M, Kopecek M, Stopkova P, Novak T, Kozeny J, Höschl C.:Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: A pilot study. J Psych Res, 41;2007, 3-4:319-325
  53. Kopeček M., Brunovský M., Novák T., Tišlerová B., Horáček J., Höschl C.: The effect of cerebellar repetitive transcranial magnetic stimulation on electrical brain acitivity detected by low resolution electromagnetic tomography. Psychiatrie, 10, 2006; S3:54-58.
  54. Praško J, Dockery C, Horáček J, Houbová P., Kosová J., Klaschka J., Pašková B., Prašková H., Seifertová D., Záleský R., Höschl C. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. Neuroendocrinology Lett. 27, 2006;4:473-481.
  55. Horáček J., Dockery C., Kopeček M., Španiel F., Novák T., Tišlerová B., Klírová M., Páleníček T., Höschl C.: regional brain metabolism as the predictor of performance on the Trail making Test in schizoprenia. A 18FDG PET covariation study. Neuroendocrinology Letters, 27; 2006, 5:587-594.
  56. Höschl C., Lopez-Ibor JJL (editors): Proceedings of 15th European Congress in Psychiatry. European psychiatry, 22, 2007, Suppl.1, p. S1-S342
  57. Höschl C. Psychiatric diagnosis and classification from the European perspective. (Diskussions-forum). Die Psychiatrie, 2007, 2:113-115. ISSN 1614-4864.
  58. Motlová L, Spaniel F, Höschl C, Balon R. Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders? Ann Clin Psychiatry. 2007 Apr-Jun;19(2):133-43.
  59. Horacek J, Brunovsky M, Novak T, Skrdlantova L, Klirova M, Bubenikova-Valesova V, Krajca V, Tislerova B, Kopecek M, Spaniel F, Mohr P, Höschl C. Effect of Low-Frequency rTMS on Electromagnetic Tomography (LORETA) and Regional Brain Metabolism (PET) in Schizophrenia Patients with Auditory Hallucinations. Neuropsychobiology 2007, Jul 19;55(3-4):132-142 [Epub ahead of print]
  60. Spaniel F, Tintera J, Hajek T, Horacek J, Dezortova M, Hajek M, Dockery C, Kozeny J, Höschl C. Language lateralization in monozygotic twins discordant and concordant for schizophrenia. A functional MRI pilot study. Eur Psychiatry. 22, 2007; 5:319-322.
  61. Španiel F, Novák T, Motlová L, Hrdlička J, Höschl C: Information Technology Aided Relapse Prevention Program in Schizophrenia (ITAREPS): reliability and validity of the early warning signs questionnaire. Psychiatrie, 11, 2007; 3:157-159.
  62. Spaniel F, Vohlídka P, Hrdlička J, Kožený J, Novák T, Motlová L, Cermák J, Bednařík J, Novák D, Höschl C. ITAREPS: Information Technology Aided Relapse Prevention Programme in Schizophrenia. Schizophr Res. 2008 Jan;98(1-3):312-7.
  63. Bauer M. et al.: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.The World Journal of Biological Psychiatry, 2007; 8(2): 67-104
  64. Hájek T., Kožený J., Kopeček M., Alda M., Höschl C.: Reduced subgenual cingulate volumes in mood disorders: a meta-analysis. J Psychiatry Neurosci 2008; 33, 2:91-99.
  65. Höschl C., Švestka J.: Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev. Neurotherapeutics 8, 2008; 4:537-552. ISSN 1473-7175.
  66. Höschl C., Robert P.H.: Proceedings of 16th European Congress of Psychiatry. Eur Psych, 23, 2008; S2: S1-S410
  67. Bares M, Brunovsky M, Kopecek M, Novak T, Stopkova P, Kozeny J, Sos P, Krajca V, Höschl C.Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry. 2008;23,5:350-355
  68. Bubeníková-Valešová V, Horáček J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors, Neurosci. Biobehav. Rev..2008, 32:1014-1023.
  69. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ,Olie JP, Fleischhacker WW, Moeller HJ.World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.Schizophr Res. 2008;100(1-3):20-38.
  70. Möller H-J et al.Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258 Suppl 3:3-23
  71. Spaniel F, Vohlídka P, Kožený J, Novák T, Hrdlička J, Motlová L, Cermák J, Höschl C.The Information Technology Aided Relapse Prevention Programme in Schizophrenia:an extension of a mirror-design follow-up.Int J Clin Pract. 62, 2008;12:1943-1946
  72. Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Höschl C. Amygdala volumes in mood disorders - Meta-analysis of magnetic resonance volumetry studies. J Affect Disord. 115, 2009:395-410. [Epub ahead of print Nov 17,2008]
  73. Závěšická L., Brunovský M., Horáček J., Matoušek M., Šóš P., Krajča V., Höschl C. Trazodone improves the results of cognitive behavioural therapy of primary insomnia in non-depressed patients. Neuroendocrinology Letters 2008; 29:6.
  74. Bares M, Kopecek M, Novak T, Stopkova P, Sos P, Kozeny J, Brunovsky M, Höschl C: Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: A double-blind, single-centre, randomized study. J. Affect. Disord. (2009), doi:10.1016/j.jad.2009.01.032 [Epub ahead of print]
  75. Kopřivová J, Horáček J, Tintěra J, Praško J, Raszka M, Ibrahim I, Höschl C. Medial frontal and dorsal cortical morphometric abnormalities are related to obsessive-compulsive disorder. Neurosci Lett. 464; 2009, 1:62-66
  76. Hajek T, Novak T, Kopecek M, Gunde E, Alda M, Höschl C. Subgenual cingulate volumes in offspring of bipolar parents and in sporadic bipolar patients. Eur Arch Psychiatry Clin Neurosci (2010) 260:297–304
  77. Höschl C. European psychiatry: needs, challenges and structures. Eur Arch Psychiatry Clin Neurosci (2009) 259 (Suppl 2):S119-S122.
  78. Horáček J, Španiel F, Novák T, Brunovský M, Minárik M, Mohr P, Páleníček T, Bubeníková-Valešová V, Vrajová M, Höschl C. The influence of polymorphism for gene RGS4 (Regulator of G-protein signaling 4) on regional brain metabolism (18FDG PET) and phenotypic variables in schizoprenia. Psychiatrie, 13, 2009; S3:141-145.
  79. Horacek J, Brunovsky M, Novak T, Tislerova B, Palenicek T, Bubenikova-Valesova V, Spaniel F, Koprivova J, Mohr P, Balikova M and Hoschl C. Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect. Psychological Medicine (2010), 40: 1443-1451
  80. Vrajová M, Stastny F, Horacek J, Lochman J, Sery O, Pekova S, Klaschka J, Höschl C: Experession of the Hippocampal NMDA Receptor GluN1 Subunit and Its Splicing Isoforms in Schizophrenia: Postmortem Study. Neurochem Res. 2010;35:994–1002
  81. Bares M, Brunovsky M, Novak T, Kopecek M, Stopkova P, Sos P, Krajca V, Höschl C.The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. Eur Neuropsychopharmacol. (2010) 20: 459–466.
  82. Gunde E, Novak T, Kopecek M, Schmidt M, Propper L, Stopkova P, Höschl C, Duffy A, Alda M, Hajek T. White matter hyperintensities in affected and unaffected late teenage and early adulthood offspring of bipolar parents: A two-center high-risk study. J Psychiatr Res. 2011 Jan;45(1):76-82
  83. Bares M, Novak T, Kopecek M, Stopkova P, Höschl C. Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study. Int J Psych Clin Pract, 14, 2010; 4:303-308
  84. Páleníček T, Balíková M, Rohanová M, Novák T, Horáček J, Fujáková M, Höschl C. Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats. Pharmacol Biochem Behav, 98, 2011: 130-139
  85. Horacek J, Preiss M, Tintera J, Laing H, Kopecek M, Spaniel F, Brunovsky M, Höschl C. A Functional Magnetic Resonance Imaging Study of the Cognitive Estimation. Act Nerv Super Rediviva 2010; 52(3): 187–192
  86. Fears R, Höschl C. Mental health policy issues: the view from FEAM. Eur Psychiatry 2011, vol 26, issue 1, pp.III-VI
  87. Spaniel F, Horáček J, Tintěra J, Ibrahim I, Novák T, Cermák J, Klírová M, Höschl C. Genetic variation in FOXP2 alters grey matter concentrations in schizophrenia patients. Neuroscience Letters 493 (2011) 131–135
  88. Kopřivová J, Congedo M, Horáček J, Praško J, Raszka M, Brunovský M, Kohútová B, Höschl C. EEG source analysis in obsessive-compulsive disorder. Clin Neurophysiol. 2011 Sep;122(9):1735-43.
  89. Páleníček T, Fujáková M, Brunovský M, Balíková M, Horáček J, Gorman I, Tylš F, Tišlerová B, Soš P, Bubeníková-Valešová V, Höschl C, Krajča V. Electroencephalographic Spectral and Coherence Analysis of Ketamine in Rats: Correlation with Behavioral Effects and Pharmacokinetics. Neuropsychobiology. 2011 Mar 22;63(4):202-218
  90. Horáček J, Flegr J, Tintěra J, Verebova K, Španiel F, Novák T, Brunovský M, Bubeníková-Valešová V, Holub D, Páleníček T, Höschl C. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: Voxel-based-morphometry (VBM) study. World J Biol Psychiatry. 2012 Oct;13(7):501-9. Epub 2011 May 23.
  91. Hájek T, Kopeček M, Höschl C. Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: Meta-analysis. World J Biol Psychiatry. 2012 Mar;13(3):178-87.
  92. Fears R, Hoschl C. European mental health policy: opportunities for science and innovation, challenges for implementation. The European Journal of Public Health 2011; doi: 10.1093/eurpub/ckr075
  93. Horacek J,Tejkalova H, Novak T, Bubenikova-Valesova V, Palenicek T, Rambousek L, Ruzickova S, Vaculin S, Höschl C. The influence of a subanaesthetic dose of ketamine on circulating pro-inflammatory cytokines and serotonin in brain reply. Psychological Medicine (2011), 41: 1787-1789.
  94. Vrajová M, Peková S, Horáček J, Höschl C. The effects of siRNA-mediated RGS4 gene silencing on the whole genome transcription profile: implications for schizophrenia. Neuroendocrinol Lett 2011; 32(3):246–252
  95. Bares M, Novak T, Brunovsky M, Kopecek M, Stopkova P, Krajca V, Höschl C. The change of QEEG prefrontal cordance as a response predictor to antidepressive intervention in bipolar depression. A pilot study, Journal of Psychiatric Research 46 (2011):219-225
  96. Bares M, Novak T, Kopecek M, Stopkova P, Kozeny J, Höschl C. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. Eur Psychiatry 27, 2012;7:522-527
  97. Baghai T, Blier P, Baldwin DS, Bauer M, Goodwin G, Fountoulakis K, Kasper S, Leonard BE, Malt U, Stein D, et al. Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. Eur Arch Psychiatry Clin Neurosci, Eur Arch Psychiatry Clin Neurosci, 2012;262,1:13-22
  98. Höschl C, Fialová L. European Psychiatric Association guidance on the conflicts of interest. European Psychiatry 27 (2012): 142–146.
  99. Baghai TC. et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2011 Nov; 261 Suppl 3:207-45.
  100. Möller HJ, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression.Eur Psychiatry, 2012 Feb;27(2):114-28.
  101. Bares M, Novak T, Kopecek M, Stopkova P, Cermak J, Kozeny J, Höschl C. Antidepressant combinations and monotherapy in the treatment of resistant depression: a randomised, open-label study. Int J Psychiatry Clin Pract. 2012 Apr 10. [Epub ahead of print]
  102. Hajek T, Kopecek M, Höschl C, Alda M. Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis. J Psychiatry Neurosci, 37; 2012, 3:1-11.
  103. Mohr P, Höschl C, Volavka J. Teaching critical appraisal of articles on psychopharmacology. Acad Psychiatry. 2012 Mar 1;36(2):114-7.
  104. Hajek T, Cullis J, Novak T, Kopecek M, Höschl C, Blagdon R, O'Donovan C, Bauer M, Young LT, Macqueen G, Alda M. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord. 2012 May;14(3):261-270.
  105. Páleníček T, Fujáková M, Brunovský M, Horáček J, Gorman I, Balíková M, Rambousek L, Syslová K, Kačer P, Zach P, Bubeníková-Valešová V, Tylš F, Kubešová A, Puskarčíková J, Höschl C. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (Berl).2013; 225(1):75-93
  106. Spaniel F, Hrdlička J, Novák T, Kožený J, Höschl C, Mohr P, Motlová LB. Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, Controlled, Double-Blind Study. J Psychiatr Pract. 2012 Jul;18(4):269-80.
  107. Höschl C, Winkler P, Pěč O. The state of psychiatry in the Czech Republic. Int Rev Psychiatry. 2012 Aug;24(4):278-85.
  108. Klirova M, Horacek J, Novak T, Cermak J, Spaniel F, Skrdlantova L, Mohr P, Höschl C. Individualized rTMS neuronavigated according to regional brain metabolism ([18]FGD PET) has better treatment effects on auditory hallucinations than standard positioning of rTMS: a double-blind, sham-controlled study. Eur Arch Psychiatry Clin Neurosci. 2012 Sep 15. [Epub ahead of print]
  109. Holub D, Flegr J, Dragomirecká E, Rodriguez M, Preiss M, Novák T, Čermák J, Horáček J, Kodym P, Libiger J, Höschl C, Motlová LB. Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia. Acta Psychiatr Scand. 2012 Nov 5. doi: 10.1111/acps.12031. [Epub ahead of print]
  110. Hajek T, Cullis J, Novak T, Kopecek M, Blagdon R, Propper L, Stopkova P, Duffy A, Hoschl C, Uher R, Paus T, Young LT, Alda M. Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. Biol Psychiatry. 2013 Jan 15;73(2):144-152
  111. Hajek T, Kopecek M, Alda M, Uher R, Höschl C. Why negative meta-analyses may be false? Eur Neuropsychopharmacol. 2013 Feb 9. pii: S0924-977X(13)00039-4. doi: 10.1016/j.euroneuro.2013.01.004. [Epub ahead of print]
  112. Fountoulakis KN, Hoschl C, Kasper S, Lopez-Ibor J, Möller HJ. The media and intellectuals' response to medical publications: the antidepressants' case. Ann Gen Psychiatry. 2013 Apr 12;12(1):11.
  113. Bauer M et al.; World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013 Jul;14(5):334-85. doi: 10.
  114. Kožený J., Tišanská L., Höschl C.: Assessing empathy among Czech medical students: a cross-sectional study. Československá psychologie, 57; 2013, 3:246-254.
  115. Bares M, Brunovsky M, Novak T, Kopecek M,Stopkova P, Sos P,Höschl C. QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder. Clinical EEG and Neuroscience, 2015, Vol. 46(2): 73–80
  116. Brunovský M, Horáček J, Nová T, Klírová M, Kohútová B, Krajča V, Höschl C. Modulating cortical connectivity in schizophrenic patients with auditory hallucinations by rTMS assessed with exact low-resolution brain tomography (eLORETA). Clinical Neurophysiology, 125,2014;5:e39–e40
  117. Stein DJ, Ahokas A, Márquez MS, Höschl C, Oh KS, Jarema M, Avedisova AS, Albarran C, Olivier V. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014 Apr;75(4):362-368. doi: 10.4088/JCP.13m08433.
  118. Bares M, Novak T, Kopecek M, Brunovsky M, Stopkova P, Höschl C. The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data. Eur Arch Psychiatry Clin Neurosci (2015) 265:73–82
  119. Fountoulakis KN, Kawohl W, Theodorakis PN, Kerkhof AJFM, Navickas A, Höschl C, et al. Relationship of suicide rates to economic variables in Europe: 2000-2011. BJPsych, published online October 30, 2014 at DOI: 10.1192/bjp.bp.114.147454
  120. Horacek J, Mikolas P, Tintera J, Novak T, Palenicek T, Brunovsky M, Höschl C, Alda M. Sad mood induction has an opposite effect on amygdala response to emotional stimuli in euthymic patients with bipolar disorder and healthy controls. J Psychiatry Neurosci. 2015 Mar;40(2):134-42.
  121. Melicher T, Horacek J, Hlinka J, Spaniel F, Tintera J, Ibrahim I, Mikolas P, Novak T, Mohr P, Hoschl C. White matter changes in first episode psychosis and their relation to the size of sample studied: A DTI study. Schizophrenia Research 2015 Mar;162(1-3):22-28
  122. Höschl C, Kane J, Gaebel W, Gorwood P, and Kennedy S. Hot Debates in CNS Disorders: Is Cognitive Impairment in Mental Disorders an Endophenotype or an Epiphenomenon? The Institute Magazine (ISSN: 1603-2683), 19; Feb 2015: 4-16
  123. Bhugra D, Ventriglio A, Kuzman MR, Ikkos G, Hermans MH, Falkai P, Fiorillo A, Musalek M, Hoschl C, Dales J, Beezhold J, Rössler W, Racetovic G, Gaebel W. EPA guidance on the role and responsibilities of psychiatrists. Eur Psychiatry. 2015 Mar;30(3):417-422.
  124. Hajek T, Cooke C, Kopecek M, Novak T, Hoschl C, Alda M. Using structural MRI to identify individuals at genetic risk for bipolar disorders: a 2-cohort, machine learning study. J Psychiatry Neurosci. 2015 Apr 8;40(2):140-142.
  125. Winkler P, Mladá K, Csémy L, Nechanská B, Höschl C. Suicides following inpatient psychiatric hospitalization: A nationwide case control study. J Affect Disord. 2015 Jun 10;184:164-169. doi: 10.1016/j.jad.2015.05.039. [Epub ahead of print]
  126. Spaniel F, Novak T, Bankovska Motlova L, Capkova J, Slovakova A, Trancik P, Matejka M, Höschl C. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system. J Psychiatr Ment Health Nurs. 2015 Dec;22(10):811-820. doi: 10.1111/jpm.12251. [Epub ahead of print] PubMed PMID: 26176646.
  127. Spaniel F, Tintera J, Rydlo J, Ibrahim I, Kasparek T, Horacek J, Zaytseva Y, Matejka M, Fialova M, Slovakova A, Mikolas P, Melicher T, Görnerova N, Höschl C, Hajek T. Altered Neural Correlate of the Self-Agency Experience in First-Episode Schizophrenia-Spectrum Patients: An fMRI Study. Schizophrenia Bulletin, Dec 2015, doi:10.1093/schbul/sbv188
  128. Winkler P, Mladá P, Krupchanka D, Agius M, Ray MK, Höschl C. Long-term hospitalizations for schizophrenia in the Czech Republic 1998–2012. Schizophrenia Research, in press. DOI:
  129. Spaniel F, Bakstein E, Anyz J, Hlinka J, Sieger T, Hrdlicka J, Görnerová N, Höschl C. Relapse in schizophrenia: definitively not a bolt from the blue. Neurosci Letters in press, April 12, 2016 doi:10.1016/j.neulet.2016.04.044
  130. Winkler P, Barrett B, McCrone P, Csémy L, Janous̆ková M, Höschl C. Deinstitutionalised patients, homelessness and imprisonment: systematic review. Brit J Psychiatry, May 2016, 208 (5): 421-428; DOI: 10.1192/bjp.bp.114.161943
  131. Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, Carli V, Höschl C, Barzilay R, Balazs J, Purebl G, Kahn JP, Sáiz PA, Lipsicas CB, Bobes J, Cozman D, Hegerl U, Zohar J. Suicide prevention strategies revisited: 10-year systematic review. The Lancet Psychiatry, Published online June 8, 2016
  132. Fountoulakis KN, Chatzikosta I, Pastiadis K, Zanis P, Kawohl W, Kerkhof AJFM, Navickas A, Höschl C, et al. Relationship of suicide rates with climate and economic variables in Europe during 2000–2012. Ann Gen Psychiatry (2016) 15:19. DOI 10.1186/s12991-016-0106-2
  133. Bares M, Novak T, Brunovsky M, Kopecek M, Höschl C. The Comparison of Effectiveness of Various Potential Predictors of Response to Treatment With SSRIs in Patients With Depressive Disorder. J Nerv Ment Dis. 2017 Aug;205(8):618-626. doi: 10.1097/NMD.0000000000000574.
  134. Winkler P, Krupchanka D, Roberts T, Kondratova L, Machů V, Höschl C, Sartorius N, et al. A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe. The Lancet Psychiatry 2017, DOI:
  135. Krzak AM, Cao JJL, Agius M, Hoschl C. Does neurogenesis relate to depression and do antidepressants affect neurogenesis? Psychiatr Danub. 2017 Sep;29(Suppl 3):241-246.
  136. Mutlu O, Páleníček T, Pinterová N, Šíchová K, Horáček J, Holubová K, Höschl C, Stuchlík A, Erden F, Valeš K. Effects of the adipokinetic hormone/red pigment-concentrating hormone (AKH/RPCH) family of peptides on MK-801-induced schizophrenia models. Fundam Clin Pharmacol. 2018;32, 6:589-602
  137. Lehmann I., Chisholm D., Hinkov H., Höschl C., Kapócs G., Kurimay T., Lecic-Tosevski D., Nakov V., Réthelyi J.M., Winkler P., Zielasek J. & Gaebel W. DEVELOPMENT OF QUALITY INDICATORS FOR MENTAL HEALTHCARE IN THE DANUBE REGION. Psychiatria Danubina, 2018; Vol. 30, No. 2, pp 197-206.
  138. van Erp TGM, …, Hoschl C, …, Spaniel F, …, Turner JA. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, in press, available online on May 18, 2018.
  139. Stein DJ, Khoob J-P, Ahokas A, Jarema M, Van Ameringen M, Vavrusova L, Hӧschl C et al. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharmacol, 28, 2018; 8: 970-979
  140. Kožený J, Tišanská L, Bednařík J, Höschl C. A Rasch analysis of the Q-LES-Q-SF questionnaire in a cohort of patients with neuropathic pain. Cesk Slov Neurol N 2019; 82/115(1): 60–67